stoxline Quote Chart Rank Option Currency Glossary
  
ENDRA Life Sciences Inc. (NDRA)
5.5  -0.02 (-0.36%)    05-29 16:00
Open: 5.78
High: 5.78
Volume: 9,832
  
Pre. Close: 5.52
Low: 5.41
Market Cap: 4(M)
Technical analysis
2026-05-29 4:45:46 PM
Short term     
Mid term     
Targets 6-month :  7.12 1-year :  8.32
Resists First :  6.09 Second :  7.12
Pivot price 5.41
Supports First :  5.16 Second :  4.58
MAs MA(5) :  5.4 MA(20) :  5.28
MA(100) :  4.46 MA(250) :  4.89
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  47.4 D(3) :  43.1
RSI RSI(14): 55
52-week High :  11.96 Low :  2.96
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NDRA ] has closed below upper band by 41.3%. Bollinger Bands are 22.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.79 - 5.82 5.82 - 5.84
Low: 5.34 - 5.37 5.37 - 5.4
Close: 5.45 - 5.5 5.5 - 5.55
Company Description

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Headline News

Thu, 28 May 2026
ENDRA Life Sciences Raises $3.8 Million in Private Placement; Sets Cash Safeguards in Side Letter - TradingView

Thu, 28 May 2026
ENDRA Life Sciences (NASDAQ: NDRA) raises $3.8M to bolster equity for Nasdaq - Stock Titan

Wed, 27 May 2026
NDRA News | ENDRA LIFE SCIENCES INC (NASDAQ:NDRA) - ChartMill

Tue, 26 May 2026
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW! - FinancialContent

Tue, 26 May 2026
[RW] ENDRA Life Sciences Inc. SEC Filing - Stock Titan

Mon, 18 May 2026
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 14.5 (%)
Held by Institutions 16.5 (%)
Shares Short 37 (K)
Shares Short P.Month 53 (K)
Stock Financials
EPS -8.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.91
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -86.8 %
Return on Equity (ttm) -291.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.62
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.62
PEG Ratio 0
Price to Book value 2.86
Price to Sales 0
Price to Cash Flow -1.32
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android